Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.00

+8.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (3612)	4/27/2001 2:44:59 PM
From: Michael Young	Read Replies (2) of 52153

Since we are discussing cramer, this is what he said today re PFE: <<Buying MORE pfizer here as the feedback I get on Geodon is amazing! I am not alone in seeing the remarkable effects of this great anti-psychotic. People from all over the country who were on Zyprexa who are now telling me about their weight loss with Geodon. (Zyprexa makes most people gain weight.) Nobody is using big numbers for Geodon in their projections. This reminds me of 1985-86 when no one was using big numbers for Mevacor -Lovastatin (anti-cholesteral) drugs for Merck and the stock had a multi-year run . . . >> Any idea what are the annual sales for Zypreza? MIKE

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next